This Obesity Drug May Have a Unique Edge

This Obesity Drug May Have a Unique Edge

Hello, it’s Sonja in Frankfurt, bringing back insights from a trip to the German town of Ingelheim about an emerging competitor in the market for weight-loss drugs. More on that in a bit, but first...

University of Toronto - Breakthrough Prize recognizes Daniel Drucker for work leading to diabetes, anti-obesity drugs

Daniel Drucker, the Canadian scientist renowned for discoveries that sparked the advent of Ozempic and other GLP-1 medicines for diabetes and obesity, has added yet another accolade to his growing. . .

A drug well-known for its "anti-obesity" properties has indirectly earned five international researchers one of the most lucrative prizes in biomedical research. For their various contributions to the discovery and use of a hormone that is now the basis for the success of drugs against diabetes, and especially obesity—including Ozempic, Wegovy, and Mounjaro—Canadian endocrinologist Daniel Drucker of the University of Toronto, his American collea…